Agios PharmaceuticalsAGIO
About: Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Employees: 386
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
15% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 67
4% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 26
2% more capital invested
Capital invested by funds: $2.53B [Q2] → $2.58B (+$44.7M) [Q3]
0% more funds holding
Funds holding: 204 [Q2] → 205 (+1) [Q3]
1.52% less ownership
Funds ownership: 103.46% [Q2] → 101.94% (-1.52%) [Q3]
15% less call options, than puts
Call options by funds: $17.8M | Put options by funds: $21.1M
33% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
RBC Capital Gregory Renza 37% 1-year accuracy 30 / 82 met price target | 67%upside $57 | Outperform Maintained | 10 Dec 2024 |
Scotiabank Greg Harrison 33% 1-year accuracy 9 / 27 met price target | 119%upside $75 | Sector Outperform Maintained | 9 Dec 2024 |
Raymond James Danielle Brill 50% 1-year accuracy 7 / 14 met price target | 49%upside $51 | Outperform Reinstated | 10 Oct 2024 |
Leerink Partners Andrew Berens 40% 1-year accuracy 2 / 5 met price target | 64%upside $56 | Market Perform Downgraded | 27 Sept 2024 |
Financial journalist opinion
Based on 6 articles about AGIO published over the past 30 days